Ashwin Ravichandran

2.4k total citations · 1 hit paper
77 papers, 1.1k citations indexed

About

Ashwin Ravichandran is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Biomedical Engineering. According to data from OpenAlex, Ashwin Ravichandran has authored 77 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Surgery, 37 papers in Cardiology and Cardiovascular Medicine and 36 papers in Biomedical Engineering. Recurrent topics in Ashwin Ravichandran's work include Mechanical Circulatory Support Devices (35 papers), Cardiac Structural Anomalies and Repair (27 papers) and Pulmonary Hypertension Research and Treatments (17 papers). Ashwin Ravichandran is often cited by papers focused on Mechanical Circulatory Support Devices (35 papers), Cardiac Structural Anomalies and Repair (27 papers) and Pulmonary Hypertension Research and Treatments (17 papers). Ashwin Ravichandran collaborates with scholars based in United States, Switzerland and United Kingdom. Ashwin Ravichandran's co-authors include Jennifer Cowger, Christopher T. Salerno, Aaron B. Waxman, Steven D. Nathan, C. Q. Deng, Thenappan Thenappan, Victor F. Tapson, Peter Smith, Rahul Argula and Peter A. Engel and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Ashwin Ravichandran

70 papers receiving 1.1k citations

Hit Papers

Inhaled Treprostinil in Pulmonary Hypertension Due to Int... 2021 2026 2022 2024 2021 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
    2021 336 citations Ashwin Ravichandran et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ashwin Ravichandran United States 16 588 497 445 375 219 77 1.1k
Kamen Valchanov United Kingdom 13 444 0.8× 368 0.7× 143 0.3× 179 0.5× 215 1.0× 56 754
Rajko Radovancevic United States 20 1.2k 2.0× 915 1.8× 101 0.2× 682 1.8× 431 2.0× 78 1.7k
Bansi Koul Sweden 19 992 1.7× 458 0.9× 481 1.1× 361 1.0× 114 0.5× 54 1.3k
Adrian Pick Australia 16 639 1.1× 177 0.4× 297 0.7× 417 1.1× 46 0.2× 34 967
Oliver Miera Germany 25 866 1.5× 655 1.3× 681 1.5× 617 1.6× 259 1.2× 109 1.7k
Barry A. Boilson United States 22 1.3k 2.3× 968 1.9× 125 0.3× 776 2.1× 423 1.9× 66 1.8k
Patrick M. McCarthy United States 19 1.4k 2.3× 914 1.8× 274 0.6× 753 2.0× 363 1.7× 40 1.9k
Sofia Carolina Masri United States 15 527 0.9× 309 0.6× 123 0.3× 384 1.0× 148 0.7× 32 908
Eduardo Barge‐Caballero Spain 20 631 1.1× 322 0.6× 69 0.2× 485 1.3× 113 0.5× 120 1.1k
Achim Koch Germany 20 637 1.1× 229 0.5× 73 0.2× 320 0.9× 93 0.4× 80 1.1k

Countries citing papers authored by Ashwin Ravichandran

Since Specialization
Citations

This map shows the geographic impact of Ashwin Ravichandran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashwin Ravichandran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashwin Ravichandran more than expected).

Fields of papers citing papers by Ashwin Ravichandran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashwin Ravichandran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashwin Ravichandran. The network helps show where Ashwin Ravichandran may publish in the future.

Co-authorship network of co-authors of Ashwin Ravichandran

This figure shows the co-authorship network connecting the top 25 collaborators of Ashwin Ravichandran. A scholar is included among the top collaborators of Ashwin Ravichandran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashwin Ravichandran. Ashwin Ravichandran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Paoli, Carly J., Wenze Tang, Sumeet Panjabi, & Ashwin Ravichandran. (2025). Assessing Upfront Treatment Patterns for Newly Initiated Patients With Pulmonary Arterial Hypertension in the United States. Journal of health economics and outcomes research. 213–221.
2.
Patel, Snehal R., David A. Baran, Palak Shah, et al.. (2025). Multimodal molecular testing provides prognostic value for heart transplant recipients. The Journal of Heart and Lung Transplantation. 45(3). 388–400.
3.
Bagchi, Pramita, Snehal R. Patel, Evgenij Potapov, et al.. (2024). Defining Optimal Criteria for LVAD Weaning in HF Patients with an Improvement in Cardiac Structure and Function: A VAD Wean Registry Analysis. The Journal of Heart and Lung Transplantation. 43(4). S83–S84.
4.
Ravichandran, Ashwin, et al.. (2024). BIOSURFACTANTS: SUSTAINABLE ALTERNATIVE TO SYNTHETIC SURFACTANTS AND THEIR APPLICATIONS. International Journal of Applied Pharmaceutics. 34–43. 5 indexed citations
5.
Khush, Kiran K., Shelley Hall, Andrew Kao, et al.. (2024). Surveillance with dual noninvasive testing for acute cellular rejection after heart transplantation: Outcomes from the Surveillance HeartCare Outcomes Registry. The Journal of Heart and Lung Transplantation. 43(9). 1409–1421. 12 indexed citations
6.
Frantz, Robert P., Shashank Desai, Gregory A. Ewald, et al.. (2024). SOPRANO: Macitentan in patients with pulmonary hypertension following left ventricular assist device implantation. Pulmonary Circulation. 14(4). e12446–e12446. 2 indexed citations
7.
Coons, James C., Meredith Broderick, Dasom Lee, et al.. (2024). Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensus. Respiratory Medicine. 231. 107734–107734. 1 indexed citations
8.
Wald, Joyce, Mosi K. Bennett, Jay D. Pal, et al.. (2024). Access to durable LVAD therapy for patients with limited social support: Surveying program-specific approaches. The Journal of Heart and Lung Transplantation. 43(6). 996–998. 1 indexed citations
9.
Franco, Verónica, Vijay Balasubramanian, Ronald Zolty, et al.. (2023). Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil. Respiratory Medicine. 218. 107374–107374. 3 indexed citations
10.
Segar, Matthew W., Muhammad Shahzeb Khan, Kershaw V. Patel, et al.. (2023). A Phenomapping Tool and Clinical Score to Identify Low Diuretic Efficiency in Acute Decompensated Heart Failure. JACC Heart Failure. 12(3). 508–520. 13 indexed citations
11.
Ramu, Bhavadharini, Rebecca Cogswell, Ashwin Ravichandran, et al.. (2023). Clinical Outcomes With a Fully Magnetically Levitated Left Ventricular Assist Device Among Women and Men. JACC Heart Failure. 11(12). 1692–1704. 6 indexed citations
12.
Allen, Steven R., Mark S. Slaughter, Mustafa M. Ahmed, et al.. (2022). COMPETENCE Trial: The EVAHEART 2 continuous flow left ventricular assist device. The Journal of Heart and Lung Transplantation. 42(1). 33–39. 17 indexed citations
13.
Gopinathannair, Rakesh, Naga Venkata K. Pothineni, Jaimin R. Trivedi, et al.. (2022). Amiodarone Use and All‐Cause Mortality in Patients With a Continuous‐Flow Left Ventricular Assist Device. Journal of the American Heart Association. 11(11). e023762–e023762. 7 indexed citations
14.
McLaughlin, Vallerie V., Richard N. Channick, Nick H. Kim, et al.. (2022). Safety of macitentan for the treatment of pulmonary hypertension: Real‐world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS). Pulmonary Circulation. 12(4). e12150–e12150. 14 indexed citations
15.
Thomas, Jordan, Donna Mancini, Noah Moss, et al.. (2022). Safety and effects of SGLT-2 inhibitor use among LVAD patients with type 2 diabetes mellitus. SHILAP Revista de lepidopterología. 18. 100154–100154. 8 indexed citations
16.
Sheikh, Farooq H., Ashwin Ravichandran, Daniel J. Goldstein, et al.. (2021). Impact of Race on Clinical Outcomes After Implantation With a Fully Magnetically Levitated Left Ventricular Assist Device: An Analysis From the MOMENTUM 3 Trial. Circulation Heart Failure. 14(10). e008360–e008360. 10 indexed citations
17.
Patel, Amit, Sunit‐Preet Chaudhry, Giorgio Zanotti, et al.. (2019). Hepatitis C donor viremic cardiac transplantation: A practical approach. Clinical Transplantation. 34(1). e13764–e13764. 15 indexed citations
18.
Ahmed, Mustafa M., Henri Roukoz, Jaimin R. Trivedi, et al.. (2019). Questionable utility of digoxin in left-ventricular assist device recipients: A multicenter, retrospective analysis. PLoS ONE. 14(11). e0225628–e0225628. 3 indexed citations
19.
Ravichandran, Ashwin, et al.. (2019). PHEOCHROMOCYTOMA CRISIS RESULTING IN A REVERSE-TAKOTSUBO CARDIOMYOPATHY REQUIRING EXTRACORPOREAL MEMBRANE OXYGENATION. Journal of the American College of Cardiology. 73(9). 2183–2183. 1 indexed citations
20.
Gopinathannair, Rakesh, Henri Roukoz, Jaimin R. Trivedi, et al.. (2019). Impact of QRS Duration and Ventricular Pacing on Clinical and Arrhythmic Outcomes in Continuous Flow Left Ventricular Assist Device Recipients: A Multicenter Study. Journal of Cardiac Failure. 25(5). 355–363. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kamen Valchanov Breakdown of academic impact, for papers by Rajko Radovancevic Breakdown of academic impact, for papers by Bansi Koul Breakdown of academic impact, for papers by Adrian Pick Breakdown of academic impact, for papers by Oliver Miera Breakdown of academic impact, for papers by Barry A. Boilson Breakdown of academic impact, for papers by Patrick M. McCarthy Breakdown of academic impact, for papers by Sofia Carolina Masri Breakdown of academic impact, for papers by Eduardo Barge‐Caballero Breakdown of academic impact, for papers by Achim Koch
Rankless by CCL
2026